VPRIV Drug Profile

Summary for Tradename: VPRIV

High Confidence Patents:	30
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for VPRIV

See drug prices for VPRIV

Pharmacology for VPRIV

Established Pharmacologic Class

Hydrolytic Lysosomal Glucocerebroside-specific Enzyme

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VPRIV Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VPRIV Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,030,043	2035-04-22	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,059,772	2036-04-22	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,077,298	2033-11-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,113,007	2033-11-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for VPRIV Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,406,278	2037-08-25	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,668,053	2034-05-02	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,675,328	2038-02-14	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VPRIV	velaglucerase alfa	For Injection	022575	10,700,870	2037-11-17	Patent claims search

International Patents for VPRIV

Country	Patent Number	Estimated Expiration
European Patent Office	2539369
Spain	2647823
European Patent Office	1922076
Taiwan	201433575

Market Dynamics and Financial Trajectory for VPRIV (velaglucerase alfa)

Last updated: April 18, 2026

What is VPRIV and its approved use?

VPRIV (velaglucerase alfa) is a recombinant enzyme therapy used to treat Type 1 Gaucher disease, a lysosomal storage disorder caused by deficient glucocerebrosidase activity. It is developed by Sanofi and approved by the FDA in August 2015.

Market Size and Growth Drivers

Global Gaucher Disease Market

The global market for Gaucher disease treatments, including enzyme replacement therapies (ERT), was valued at approximately $400 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4-6% from 2023 to 2030, reaching approximately $600 million by 2030.

Key Growth Factors

• Increased diagnosis rates due to enhanced awareness and genetic screening.
• Expansion in emerging markets lacking established treatment options.
• Development of alternative therapies and biosimilars, increasing competition.

Competitive Landscape

VPRIV competes primarily with:

• Cerezyme (imiglucerase), by Sanofi
• Cerdelga (eliglustat), by Takeda
• Zavesca (miglustat), by Actelion

Cerezyme remains dominant, holding roughly 60-65% of the market. Cerdelga’s oral administration offers a non-injectable alternative, gaining significant adoption.

Pricing, Revenue, and Market Penetration

Pricing

• VPRIV's list price ranges from $400,000 to $500,000 per year per patient, aligned with other ERTs.
• Price variations depend on dosing, patient weight, and healthcare system negotiations.

Revenue Trajectory

Sanofi reported VPRIV revenues of approximately €83 million (~$89 million) in 2021. Revenue declined modestly in subsequent years, partly due to market saturation and emerging biosimilar options.

Market Penetration

• VPRIV’s market share among Gaucher treatments has decreased from about 10% in 2015 to approximately 4-6% in 2022.
• Adoption is higher in regions with established healthcare infrastructure; penetration remains low in emerging markets.

Regulatory and Pipeline Considerations

• Approval extensions:** VPRIV has not received major regulatory extensions or new indications beyond the initial approval.
• Biosimilar Impact:** Biosimilar alternatives in development threaten long-term profitability.
• Pipeline Developments: No recent approvals or major pipeline updates for VPRIV have been announced, limiting future growth prospects.

Financial Outlook and Risks

Short-term outlook (2023-2025)

• Revenue stabilization expected as off-label and orphan drug policies evolve.
• Market share decline due to biosimilar entry and competition.
• Limited pipeline development restricts growth initiatives.

Long-term outlook (2026 and beyond)

• If biosimilars gain approval and market penetration, VPRIV's revenue could diminish further.
• Integration with healthcare systems in emerging markets could provide incremental growth, contingent on pricing strategies.
• No significant approval extensions or new indications limit upside potential.

Key Market Trends Affecting VPRIV

• Shift toward oral therapies (e.g., Cerdelga) reduces injections-based treatment preferences.
• Increased use of genetic testing enhances early diagnosis, boosting overarching market size.
• Pricing pressures from payers, especially in Europe and North America.

---

Key Takeaways

• VPRIV is a niche enzyme therapy for Gaucher disease with limited growth prospects.
• Market share has declined due to competition and biosimilar threats.
• Revenue is stable but expects downward pressure over the next five years.
• Pricing remains high, but payor negotiations influence profitability.
• Pipeline activity and biosimilar approval timelines are critical to future trajectory.

---

FAQs

1. What factors influence VPRIV’s market share?

Market share depends on competition from oral therapies, biosimilar entry, pricing strategies, physician preferences, and regional healthcare policies.

2. How does biosimilar development impact VPRIV?

Biosimilars can create price competition, reduce revenues, and accelerate market share erosion when approved and adopted.

3. Are there any new indications or extensions approved for VPRIV?

No, there have been no recent regulatory approvals or expanded indications since the initial approval in 2015.

4. How does pricing of VPRIV compare to competitors?

VPRIV's list price aligns with other enzyme replacement therapies, generally around $400,000–$500,000 annually. Pricing is subject to negotiation and regional healthcare policies.

5. What regions offer the most growth potential for VPRIV?

Emerging markets with limited treatment options provide growth opportunities, contingent on pricing, reimbursement, and healthcare infrastructure development.

---

References

[1] U.S. Food and Drug Administration. (2015). FDA approves VPRIV for Gaucher disease.

[2] EvaluatePharma. (2022). Gaucher disease market estimates and forecasts.

[3] Sanofi Annual Reports. (2021). VPRIV sales data and market analysis.

[4] IQVIA. (2022). Global enzyme replacement therapy market reports.

[5] European Medicines Agency. (2015). VPRIV approval documentation.